What Size of Sessile Polyps Are Cancerous?

Sessile polyps sitting flat against the colon wall become cancerous at rates that climb steeply with size, and the critical dividing line is about 10 millimeters. Below that threshold, actual cancer within a polyp is rare enough that tens of thousands of tiny polyps can be examined without finding a single one. Above it, the picture changes fast: large sessile polyps harbor invasive cancer in roughly one out of every fifteen or so cases, and polyps of any histologic type that reach 10 mm are linked to several-fold higher odds of dying from colorectal cancer. But size alone does not tell the whole story, because where a polyp sits in the colon, what kind of tissue it contains, and how completely it gets removed all shift the risk in ways that matter for your follow-up care.

Diminutive Polyps Under 5 Millimeters

Most polyps discovered during a routine colonoscopy are tiny, under 5 mm across. These “diminutive” polyps almost never contain cancer. In one large analysis of over 36,000 polyps 5 mm or smaller, researchers found zero cancers.¹ Among the conventional adenomas in that group, only about 0.3% showed high-grade dysplasia, the most worrisome precancerous change short of actual cancer. Roughly 2% were classified as “advanced” adenomas, but advanced in this context usually means the tissue looked slightly more abnormal under the microscope, not that it was malignant.

That said, zero cancer in a large study is not the same as zero cancer everywhere. A separate Korean study looking at small and diminutive polyps did find adenocarcinoma in 6 out of nearly 4,700 cases, along with high-grade dysplasia in a few more.² So it is not mathematically impossible for a tiny polyp to be cancerous, but the probability is low enough that gastroenterology guidelines now allow some diminutive polyps to be assessed visually and discarded without being sent to a pathology lab. The practical takeaway: if your colonoscopy report says a small polyp was removed and showed no concerning features, the chance it harbored cancer is vanishingly small.

Small Polyps Between 6 and 9 Millimeters

Step up one size bracket and the numbers shift, though they remain reassuring. Polyps in the 6-to-9-mm range are more likely to contain advanced features: about 5.6% of conventional adenomas this size qualify as advanced, and high-grade dysplasia appears in roughly 0.8%.¹ That is a noticeable jump from diminutive polyps, but actual cancer is still hard to find at this size.

A study that tracked 6-to-9-mm polyps, some removed immediately and some monitored with CT imaging before removal, found that among 375 polyps resected right away, not a single one contained cancer or high-grade dysplasia. The advanced histology rate was about 2%, and all of those were tubulovillous adenomas rather than malignancies.³ So while a polyp at 8 mm deserves removal and careful examination, the odds of it already being cancer remain very low.

The 10 Millimeter Threshold

Once a sessile polyp reaches a centimeter across, the landscape shifts. This is the size at which guidelines start treating polyps as higher-risk, and the data support that cutoff. In a study of 400 consecutive large, flat colorectal polyps with a median size of 35 mm, roughly 6.5% contained submucosal invasive cancer, the kind that has grown deep enough into the bowel wall to potentially spread.⁴ These were referral-center lesions, so the rate may skew higher than what a screening colonoscopy would turn up, but the contrast with the near-zero cancer rates in smaller polyps is stark.

The long-term mortality data reinforce this. A large screening-registry study found that having a polyp 10 mm or larger was associated with roughly three-and-a-half times the risk of dying from colorectal cancer for conventional adenomas, and the risk was similarly elevated for sessile serrated lesions and even for hyperplastic polyps at that size.⁵ That last finding may surprise people who think of hyperplastic polyps as universally harmless. The data suggest that at larger sizes, the link to cancer death intensifies across the board, regardless of the polyp’s histologic label.

Why the Side of the Colon Matters

If you focus only on size, you can miss a pattern that gastroenterologists have been paying increasing attention to: cancerous polyps in the right colon tend to be smaller than cancerous polyps in the left colon. A study that compared polyp size across locations found that polyps with high-grade dysplasia or adenocarcinoma in the right colon had a mean size of about 8 mm, while the same category of polyps on the left side averaged about 12 mm.⁶ The median size of cancerous right-sided polyps was only 7 mm, meaning that a polyp in the right colon that looks unremarkable by size standards may already harbor serious disease.

This has real implications for screening. A strategy that watches and waits on any polyp under 10 mm could miss right-sided cancers more often. The right colon is also harder to visualize during colonoscopy because of its anatomy and the way polyps there tend to be flatter and more sessile. These factors together help explain why right-sided colorectal cancers have historically been caught at later stages and carried a worse prognosis per size compared to left-sided ones.

Sessile Serrated Lesions and Their Own Route to Cancer

Not all sessile polyps follow the same biological path toward cancer. The traditional “adenoma-to-carcinoma” sequence involves adenomatous polyps accumulating mutations over years until they turn malignant. But sessile serrated lesions, which account for a meaningful fraction of colon polyps, follow a different molecular pathway that involves different genes and can sometimes progress to cancer more quickly. These lesions are particularly tricky because they tend to be flat, pale, and covered with a mucus cap that makes them easy to miss during colonoscopy.

For an individual sessile serrated lesion, the cancer risk still tracks with size. The screening-registry study mentioned earlier found that sessile serrated lesions and traditional serrated adenomas 10 mm or larger carried about two-and-a-half times the risk of colorectal cancer death compared to smaller ones.⁵ But the real concern emerges when someone develops many of them.

Serrated polyposis syndrome, a condition where multiple serrated polyps appear throughout the colon, carries a dramatically elevated cancer risk. In one registry study, about 9% of patients with serrated polyposis had already been diagnosed with colorectal cancer by the time their syndrome was identified, and the overall rate of colorectal cancer was nearly 19 times what would be expected in the general population.⁷ These patients need aggressive ongoing surveillance. The lesson is that even polyps that individually look low-risk become a serious concern when they recur frequently and in large numbers. Sessile serrated polyps, whether sporadic or part of this syndrome, are associated with increased risk of both synchronous neoplasia (additional polyps at the same exam) and new polyps discovered at future exams.⁸

How Removal Technique Affects Outcomes

Finding a polyp is only half the job. How it gets removed determines whether it can recur, and recurrence is the bridge between a polyp that was caught in time and one that eventually turns into cancer. For smaller sessile polyps, cold snare polypectomy, where the polyp is lassoed and sliced off without electrical current, is standard and effective. But as sessile polyps grow larger, removing them in a single piece becomes more difficult, and the technique matters more.

Larger sessile polyps often have to be resected in pieces, a technique called piecemeal removal. When researchers compared outcomes of piecemeal versus en-bloc (single-piece) resection, the piecemeal group had substantially more recurrences: 12 out of 67 polyps removed in pieces recurred, compared to just 2 out of 54 removed in one piece.⁹ The mean size of piecemeal polyps was about 23 mm versus about 15 mm for en-bloc, which itself reflects the challenge: bigger polyps are harder to remove intact. For very large polyps, those over 40 mm, size alone becomes an independent risk factor for local recurrence even when the procedure goes well.¹⁰

Cold endoscopic mucosal resection, a newer cold technique that lifts the tissue with fluid injection before cutting, is gaining ground for intermediate-size sessile serrated lesions because it reduces the number of cuts needed and improves the chances of complete removal.¹¹ The common thread across all of these techniques is that incomplete removal is the enemy. A polyp fragment left behind has already demonstrated the biological ability to grow abnormally and, in the worst case, can quietly progress to cancer between surveillance visits.

What Happens After Removal

Your surveillance schedule after polypectomy depends heavily on what was found and how big it was. British Society of Gastroenterology guidelines define high-risk findings as either having two or more precancerous polyps with at least one “advanced” polyp (an adenoma 10 mm or larger, or one with high-grade dysplasia, or a serrated polyp 10 mm or larger or with any dysplasia), or having five or more precancerous polyps of any size. If you meet those criteria, the recommendation is a follow-up colonoscopy in three years. If you do not, you are directed back to the national screening program rather than early repeat colonoscopy.¹²

The 10 mm mark shows up here again as the line that separates routine from high-risk surveillance, underscoring how important accurate size measurement is at the time of the procedure. U.S. guidelines follow a broadly similar logic, though the exact intervals differ slightly. The underlying principle is the same: a polyp that crosses the centimeter boundary at removal changes your follow-up trajectory for years.

The Polyp Sizing Problem

Here is a complication that most patients never think about: the endoscopist’s estimate of polyp size during the procedure is often inaccurate. Gastroenterologists typically eyeball polyp size, sometimes placing an open biopsy forceps next to the polyp for reference. Both methods are surprisingly imprecise. Research has shown that for both experts and trainees, visual estimates of the same polyp varied significantly depending on the camera angle, and there was a consistent tendency to underestimate size, especially for polyps larger than 10 mm.¹³

This matters because a polyp that looks like 9 mm on screen might actually be 12 mm, and that difference changes whether you end up in the high-risk surveillance group or get sent home with a reassuring note. Artificial intelligence tools are being developed to address this. One AI model showed a mean measurement error of only about 0.03 mm compared to a reference standard, with error rates averaging around 11% across all size categories.¹⁴ That level of consistency is considerably better than what human estimation typically achieves, and it does not require placing a reference instrument next to the polyp. If these tools become standard, the fuzzy border between “small” and “large” polyps should sharpen, leading to more appropriate surveillance decisions.

How Endoscopists Assess Cancer Risk in Real Time

Size is the most important visual cue, but experienced endoscopists also look at surface patterns, color, and blood vessel architecture to judge whether a polyp might already be cancerous. Classification systems like the Kudo pit-pattern scheme use dye sprayed onto the polyp surface to reveal its microscopic architecture, while systems like the NICE classification use narrow-band imaging to highlight vascular patterns without dye.¹⁵ Certain patterns, like irregular or destroyed surface pits and thick, irregular vessels, raise suspicion for deep submucosal invasion, which would make the polyp unsuitable for endoscopic removal and a candidate for surgery instead.

For diminutive polyps, the question is less about detecting cancer and more about identifying whether the polyp is even an adenoma or just a harmless hyperplastic blip. Optical diagnosis strategies, where the endoscopist classifies the polyp visually and acts accordingly without waiting for lab results, have been shown to agree with pathology-based surveillance recommendations over 90% of the time.¹⁶ This means that for tiny polyps, a skilled endoscopist’s visual assessment is good enough to guide follow-up care without sending every sample to pathology, saving time and cost. A cost-effectiveness analysis estimated that adopting a “resect and discard” approach for eligible diminutive polyps would save about $25 per screened person without meaningfully changing screening accuracy, translating to tens of millions of dollars annually in the U.S.¹⁷

AI-assisted optical diagnosis is a natural extension of this idea, but the technology is not yet a clear win in real-world practice. While AI diagnostic tools perform well in controlled retrospective image analyses, prospective studies have revealed meaningful limitations: higher abstention rates (where the system declines to classify), poor specificity, and weak recognition of sessile serrated lesions in particular.¹⁸ Given that sessile serrated lesions follow their own cancer pathway and are already the polyps most likely to be missed by human eyes, an AI system that struggles with them is not yet solving the hardest part of the problem.